What is HER2-Low Breast Cancer?

HER2 Testing Breast Cancer: NEW Classifications (HER2 Low, Ultra Low) & Enhertu (Trastuzumab Deruxtecan) Explained! DESTINY-B04 & B06 Trial insights.

Dr. Francisco J. Esteva, MD, PhD (Medical Oncology), explains the evolving landscape of HER2 testing in breast cancer and its profound impact on diagnosis, treatment strategies, and personalized care. Discover the new classifications like HER2 Low and HER2 Ultra Low, and understand how they are reshaping the future of breast cancer treatment. This video dives deep into the latest advancements, including critical findings from the groundbreaking DESTINY-Breast04 and DESTINY-Breast06 clinical trials. Learn about the revolutionary impact of trastuzumab deruxtecan (Enhertu) and what these significant changes in HER2 status and targeted therapies mean for patients with breast cancer, their caregivers, and oncology professionals.

Stay informed on cutting-edge breast cancer research with insights on:
• The evolution of HER2 testing and its significance.
• Understanding HER2 Low and HER2 Ultra Low breast cancer classifications.
• Key takeaways from the DESTINY-Breast04 (DESTINY-B04) trial.
• Insights from the DESTINY-Breast06 (DESTINY-B06) trial.
• The role of Trastuzumab Deruxtecan (Enhertu) in treating HER2-expressing breast cancers.
• How these advancements lead to more personalized and effective treatment options.
• Implications for HER2-positive, HER2-low, and HER2-negative breast cancer.

#HER2 #BreastCancer #Enhertu #TrastuzumabDeruxtecan #HER2Low #DESTINYBreast04 #DESTINYBreast06 #CancerResearch #DrFranciscoEsteva #Oncology #PersonalizedMedicine #CancerTreatment

Chapters
00:00 Introduction
00:18 HER2 biology
00:35 HER2 classsification
01:21 Trastuzumab Deruxtecan
01:32 DESTINY-B04 Trial
01:55 DESTINY-B06 Trial
03:19 Is HER2 Testing Necessary?
03:56 Antibody-Drug Conjugates in Development
04:09 Combination Therapy
04:37 Implications for Patient Management
05:34 Supportive Care
05:50 Future Research Directions
07:29 Conclusion

ABOUT DR. ESTEVA:
Francisco J. Esteva, MD, PhD is a practicing physician located in New York, NY, specializing in Oncology with a focus on breast cancer. His education includes an Oncology Fellowship at Georgetown University Hospital and Internal Medicine Residency at Cooper Medical School of Rowan University. Prior to his current position as Division Chief at Lenox Hill Hospital, Dr. Esteva has held professorship positions at NYU and The University of Texas MD Anderson Cancer Center, as well as serving as VP Clinical Development for Cellectis. In addition to multiple esteemed publications, he has led more than 100 clinical trials related to breast cancer treatments, diagnostics and prognostic/predictive markers. Dr. Esteva was recognized as a Fellow by the American College of Physicians in 2002, elected as a member of The American Society for Clinical Investigation in 2010 and awarded the 2019 Physician of Impact award by the NYC chapter of the Susan G. Komen Foundation. In 2024, he was elected to the NYC American Cancer Society Board of Advisors.

⚠️ The information in this video is not intended nor implied to be a substitute for professional medical advice, diagnosis, or treatment. All content, including text, graphics, images, and information, contained in this video is for general information purposes only and does not replace a consultation with your own doctor/health professional. The views shared in this video represent Dr. Esteva's personal opinions and do not reflect those of his employer.